What is the share price of Dr. Lal PathLabs Ltd (LALPATHLAB) today?
The share price of LALPATHLAB as on 18th June 2026 is ₹1662.90. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Dr. Lal PathLabs Ltd (LALPATHLAB) share?
The past returns of Dr. Lal PathLabs Ltd (LALPATHLAB) share are- Past 1 week: 4.49%
- Past 1 month: 4.70%
- Past 3 months: 23.46%
- Past 6 months: 19.05%
- Past 1 year: 14.23%
- Past 3 years: 64.12%
- Past 5 years: 4.71%
What are the peers or stocks similar to Dr. Lal PathLabs Ltd (LALPATHLAB)?
The peers or stocks similar to Dr. Lal PathLabs Ltd (LALPATHLAB) include:What is the dividend yield % of Dr. Lal PathLabs Ltd (LALPATHLAB) share?
The current dividend yield of Dr. Lal PathLabs Ltd (LALPATHLAB) is 1.48.What is the market cap of Dr. Lal PathLabs Ltd (LALPATHLAB) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Dr. Lal PathLabs Ltd (LALPATHLAB) is ₹27595.06 Cr as of 18th June 2026.What is the 52 week high and low of Dr. Lal PathLabs Ltd (LALPATHLAB) share?
The 52-week high of Dr. Lal PathLabs Ltd (LALPATHLAB) is ₹1803 and the 52-week low is ₹1272.60.What is the PE and PB ratio of Dr. Lal PathLabs Ltd (LALPATHLAB) stock?
The P/E (price-to-earnings) ratio of Dr. Lal PathLabs Ltd (LALPATHLAB) is 54.67. The P/B (price-to-book) ratio is 12.51.Which sector does Dr. Lal PathLabs Ltd (LALPATHLAB) belong to?
Dr. Lal PathLabs Ltd (LALPATHLAB) belongs to the Health Care sector & Hospitals & Diagnostic Centres sub-sector.How to buy Dr. Lal PathLabs Ltd (LALPATHLAB) shares?
You can directly buy Dr. Lal PathLabs Ltd (LALPATHLAB) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Dr. Lal PathLabs Ltd
LALPATHLAB Share Price
NSE₹1,662.900.67% (+11.10)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
LALPATHLAB Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
LALPATHLAB Performance & Key Metrics
LALPATHLAB Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 54.67 | 12.51 | 1.48% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 40.63 | 6.08 | 0.57% |
88%
Analysts have suggested that investors can buy this stock
from 25 analysts
Price Upside
Earnings Growth
Rev. Growth
LALPATHLAB Company Profile
Dr Lal Pathlabs Private Limited is headquartered in Gurgaon, Haryana, India and is a medical laboratory operator.
APOLLOHOSP
PE Ratio
62.41
62.41
1Y Return
21.32%
21.32%
Buy Reco %
86.21
86.21
MAXHEALTH
PE Ratio
69.24
69.24
1Y Return
7.72%
7.72%
Buy Reco %
82.61
82.61
FORTIS
PE Ratio
68.82
68.82
1Y Return
26.32%
26.32%
Buy Reco %
84.21
84.21
ASTERDM
PE Ratio
102.01
102.01
1Y Return
38.41%
38.41%
Buy Reco %
100.00
100.00
PE Ratio
46.47
46.47
1Y Return
1.83%
1.83%
Buy Reco %
85.71
85.71
LALPATHLAB Sentiment Analysis
LALPATHLAB Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
LALPATHLAB Stock Summary · May 2026
Volume-driven growth with deliberate reinvestment underpinned the quarter and year, but management signalled that ongoing investments will keep margins broadly stable. Q4 revenue was Rs. 703 crore (up 16.6% year‑on‑year), and management highlighted a strong cash position of Rs. 1,526 crore to fund organic expansion and M&A. They pointed to double‑digit sample and patient volume growth and rising revenue per patient as the main revenue drivers, while emphasising network rollout—14 new labs and over 1,100 collection centres this year (about 32 labs and ~2,000 centres added over two years)—as central to future utilisation gains. Near‑term spending on infrastructure, hiring and marketing, plus a one‑time Labour Code charge and an accounting regrouping of courier costs, weighed on quarterly profit metrics even as adjusted margins improved year over year. Management described the Sovaaka premium screening pilot as operationally stabilising with no immediate roll‑out, framed a small Mumbai acquisition as a foothold to scale, and reiterated FY27 revenue guidance of 13%–15% while expecting no margin expansion as they continue investing.
LALPATHLAB Stock Growth Drivers
LALPATHLAB Stock Growth Drivers
6Robust Financial Performance and Strengthened Liquidity
The company delivered solid top-line and profitability gains with Q4 FY26 revenue of Rs.703 crore
Large-Scale Network and Capacity Expansion
The company materially expanded its diagnostic footprint and capacity during the year, adding 14 new
LALPATHLAB Stock Challenges
LALPATHLAB Stock Challenges
4Rising operating costs from labour-code change and recent network expansion
The company recorded a one-time Rs.30 crore charge related to the new Labour Code (accounted
Aggressive geographic and capability expansion with unclear returns and heightened competitive risk
The company has pursued rapid capacity expansion (32 labs added over the past two years,
LALPATHLAB Forecast
LALPATHLAB Forecasts
Price
Revenue
Earnings
LALPATHLAB Share Price Forecast
LALPATHLAB Share Price Forecast
2026
Current
₹1,662.90
Baseline
Forecast for Jun 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
2026
Current
₹1,662.90
Baseline
Forecast for Jun 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
LALPATHLAB Company Revenue Forecast
LALPATHLAB Company Revenue Forecast
2026
Current
₹2.86
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
2026
Current
₹2.86
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
LALPATHLAB Stock EPS (Earnings Per Share) Forecast
LALPATHLAB Stock EPS (Earnings Per Share) Forecast
2026
Current
₹30.24
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
2026
Current
₹30.24
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
LALPATHLAB
LALPATHLAB
Income
Balance Sheet
Cash Flow
Quarterly Normal View
LALPATHLAB Income Statement
LALPATHLAB Income Statement
Quarterly Normal View
| Quarter | dec 2023 | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | mar 2026 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 557.20 | 563.80 | 622.50 | 682.10 | 621.80 | 628.40 | 697.90 | 755.40 | 684.20 | 726.70 | ||||||||||
Operating & Other expenses | 398.30 | 400.70 | 431.90 | 457.70 | 442.70 | 433.60 | 477.50 | 506.50 | 510.60 | 515.90 | ||||||||||
EBITDA | 158.90 | 163.10 | 190.60 | 224.40 | 179.10 | 194.80 | 220.40 | 248.90 | 173.60 | 210.80 | ||||||||||
| Depreciation/Amortization | 36.00 | 36.60 | 34.70 | 35.30 | 35.50 | 36.40 | 34.60 | 40.50 | 42.10 | 44.60 | ||||||||||
| PBIT | 122.90 | 126.50 | 155.90 | 189.10 | 143.60 | 158.40 | 185.80 | 208.40 | 131.50 | 166.20 | ||||||||||
| Interest & Other Items | 7.00 | 6.60 | 6.00 | 6.00 | 5.30 | 5.00 | 4.70 | 4.80 | 7.20 | 6.10 | ||||||||||
| PBT | 115.90 | 119.90 | 149.90 | 183.10 | 138.30 | 153.40 | 181.10 | 203.60 | 124.30 | 160.10 | ||||||||||
| Taxes & Other Items | 34.60 | 35.40 | 43.50 | 53.90 | 41.60 | -1.40 | 48.70 | 53.00 | 33.80 | 28.80 | ||||||||||
| Net Income | 81.30 | 84.50 | 106.40 | 129.20 | 96.70 | 154.80 | 132.40 | 150.60 | 90.50 | 131.30 | ||||||||||
| EPS | 4.89 | 5.07 | 6.40 | 7.76 | 5.80 | 9.29 | 7.94 | 9.03 | 5.42 | 7.86 |
LALPATHLAB Company Updates
FY 2026FY 2026
Investor Presentation
Apr 30PDF
Jan 30PDF
Oct 31PDF
Jul 31PDF
LALPATHLAB Stock Peers
LALPATHLAB Past Performance & Peer Comparison
LALPATHLAB Past Performance & Peer Comparison
Comparing 3 stocks from
Health CareHospitals & Diagnostic Centres
Compare valuation on Screener
Health CareHospitals & Diagnostic Centres
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Dr. Lal PathLabs Ltd | 54.67 | 12.51 | 1.48% |
| Apollo Hospitals Enterprise Ltd | 62.41 | 10.92 | 0.24% |
| Max Healthcare Institute Ltd | 69.24 | 10.65 | 0.19% |
| Fortis Healthcare Ltd | 68.82 | 7.82 | 0.11% |
LALPATHLAB Stock Price Comparison
Compare LALPATHLAB with any stock or ETFCompare LALPATHLAB with any stock or ETF
LALPATHLAB
LALPATHLAB Holdings
LALPATHLAB Shareholdings
LALPATHLAB Promoter Holdings Trend
LALPATHLAB Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
LALPATHLAB Institutional Holdings Trend
LALPATHLAB Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Decreased Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has decreased by 3.11%
LALPATHLAB Shareholding Pattern
LALPATHLAB Shareholding Pattern
LALPATHLAB Shareholding History
LALPATHLAB Shareholding History
Foreign Institutions
Mutual Funds Invested in LALPATHLAB
Mutual Funds Invested in LALPATHLAB
No mutual funds holding trends are available
Top 5 Mutual Funds holding Dr. Lal PathLabs Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 2.4339% | Percentage of the fund’s portfolio invested in the stock 0.66% | Change in the portfolio weight of the stock over the last 3 months 0.08% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 36/78 (0) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.4859% | Percentage of the fund’s portfolio invested in the stock 1.85% | Change in the portfolio weight of the stock over the last 3 months 0.28% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 20/62 (+3) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.0601% | Percentage of the fund’s portfolio invested in the stock 1.12% | Change in the portfolio weight of the stock over the last 3 months 0.18% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 62/85 (0) |
Compare 3-month MF holding change on Screener
smallcases containing LALPATHLAB stock
smallcases containing LALPATHLAB stock
Looks like this stock is not in any smallcase yet.
LALPATHLAB Events
LALPATHLAB Events
LALPATHLAB Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
LALPATHLAB has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 1.48%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹14.84 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
LALPATHLAB Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
LALPATHLAB has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 1.48%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹14.84 every year
LALPATHLAB Upcoming Dividends
LALPATHLAB Upcoming Dividends
Cash Dividend
Ex DateEx DateJun 25, 2026
Final
Final | Div/Share: ₹4.00
Dividend/Share
₹4.00
Ex DateEx Date
Jun 25, 2026
LALPATHLAB Past Dividends
LALPATHLAB Past Dividends
Cash Dividend
Ex DateEx DateFeb 5, 2026
Interim 3
Interim 3 | Div/Share: ₹3.50
Dividend/Share
₹3.50
Ex DateEx Date
Feb 5, 2026
Cash Dividend
Ex DateEx DateNov 7, 2025
Interim 2
Interim 2 | Div/Share: ₹7.00
Dividend/Share
₹7.00
Ex DateEx Date
Nov 7, 2025
Cash Dividend
Ex DateEx DateAug 6, 2025
Interim
Interim | Div/Share: ₹6.00
Dividend/Share
₹6.00
Ex DateEx Date
Aug 6, 2025
Cash Dividend
Ex DateEx DateJun 6, 2025
Final
Final | Div/Share: ₹6.00
Dividend/Share
₹6.00
Ex DateEx Date
Jun 6, 2025
Cash Dividend
Ex DateEx DateFeb 5, 2025
Interim 3
Interim 3 | Div/Share: ₹6.00
Dividend/Share
₹6.00
Ex DateEx Date
Feb 5, 2025
LALPATHLAB Stock News & Opinions
LALPATHLAB Stock News & Opinions
Articles & Videos
Spotlight
Spotlight
Dr Lal PathLabs rises 6% in four sessionsThe stock has gained 6.01% over four sessions, 24.09% in the past three months and 10.24% so far in 2026. Investor sentiment remained positive after the diagnostics company announced on 12 June that it had incorporated a wholly owned subsidiary, DR LAL PATHLABS FZCO, in Dubai, United Arab Emirates. The new entity has been established in the Dubai Multi Commodities Centre (DMCC) and will focus on strategic investments in diagnostics and allied healthcare activities. The company said the subsidiary will explore potential acquisitions, partnerships and joint ventures in the sector. Dr Lal PathLabs has subscribed to the entire share capital of the subsidiary amounting to AED 19.135 million, divided into 19,135 shares of AED 1,000 each, giving it 100% ownership. The move marks the company's entry into the UAE through a dedicated investment vehicle and is expected to support its plans to expand its presence in international diagnostics markets. Dr Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. As on 31 March 2026 the company has 312 clinical laboratories (including National Reference Lab at Delhi, Regional Reference Lab at Kolkata, Bangalore & Mumbai), 7,727 Patient Service Centers (PSCs) and 13,935 Pick-up Points (PUPs). Its' customers include individual patients, hospitals and other healthcare providers and corporate customers. On a consolidated basis, the company posted a net profit of Rs 132 crore in Q4 FY26, down 15.1% YoY. Revenue rose 16.6% YoY to Rs 703 crore in Q4 FY26. Powered by Capital Market - Live
2 days agoCapital Market - Live
Earnings
Earnings
Dr Lal Pathlabs consolidated net profit declines 15.18% in the March 2026 quarterNet profit of Dr Lal Pathlabs declined 15.18% to Rs 131.30 crore in the quarter ended March 2026 as against Rs 154.80 crore during the previous quarter ended March 2025. Sales rose 16.61% to Rs 702.70 crore in the quarter ended March 2026 as against Rs 602.60 crore during the previous quarter ended March 2025. For the full year,net profit rose 3.63% to Rs 504.80 crore in the year ended March 2026 as against Rs 487.10 crore during the previous year ended March 2025. Sales rose 12.25% to Rs 2762.90 crore in the year ended March 2026 as against Rs 2461.40 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales702.70602.60 17 2762.902461.40 12 OPM %26.5828.05 -28.3228.26 - PBDT204.70189.80 8 861.00766.60 12 PBT160.10153.40 4 699.20624.70 12 NP131.30154.80 -15 504.80487.10 4 Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Corporate
Board of Dr Lal Pathlabs approves incorporation of WoS in DubaiThe board of Dr Lal Pathlabs at its meeting held on 30 April 2026 has approved the incorporation of wholly owned subsidiary company in Dubai in the name and style of Dr Lal Pathlabs FZCO.
1 month agoCapital Market - Live
Corporate
Corporate
Board of Dr Lal Pathlabs approves acquisition of Shahbazkers Diagnostic CentreThe board of Dr Lal Pathlabs at its meeting held on 30 April 2026 has approved the acquisition of 100% stake in Shahbazkers Diagnostic Centre (SDCPL) from its existing Shareholders. Post acquisition, SDCPL shall become a wholly owned subsidiary of the company.
1 month agoCapital Market - Live
Corporate
Corporate
Dr Lal Pathlabs fixes record date for final dividendDr Lal Pathlabs has fixed 26 June 2026 as record date for payment of final dividend of Rs 4 per equity share for FY 2026.
1 month agoCapital Market - Live
Corporate
Corporate
Dr. Lal PathLabs schedules AGMDr. Lal PathLabs announced that the 32th Annual General Meeting(AGM) of the company will be held on 25 July 2026.
1 month agoCapital Market - Live
Corporate
Corporate
Board of Dr. Lal PathLabs recommends Final DividendDr. Lal PathLabs announced that the Board of Directors of the Company at its meeting held on 30 April 2026, has recommended a Final Dividend of Rs.4 per share (i.e.40%), subject to the approval of the shareholders.
1 month agoCapital Market - Live
Spotlight
Spotlight
Volumes soar at Dr Lal Pathlabs Ltd counterTorrent Power Ltd, Tube Investments of India Ltd, Godrej Consumer Products Ltd, HCL Technologies Ltd are among the other stocks to see a surge in volumes on BSE today, 22 April 2026.Dr Lal Pathlabs Ltd recorded volume of 8.65 lakh shares by 10:47 IST on BSE, a 104.67 times surge over two-week average daily volume of 8262 shares. The stock gained 0.59% to Rs.1,448.35. Volumes stood at 7214 shares in the last session.Torrent Power Ltd recorded volume of 2.35 lakh shares by 10:47 IST on BSE, a 9.08 times surge over two-week average daily volume of 25898 shares. The stock gained 1.87% to Rs.1,652.35. Volumes stood at 12663 shares in the last session.Tube Investments of India Ltd notched up volume of 58534 shares by 10:47 IST on BSE, a 5.46 fold spurt over two-week average daily volume of 10712 shares. The stock rose 2.45% to Rs.2,955.50. Volumes stood at 12907 shares in the last session.Godrej Consumer Products Ltd witnessed volume of 2.82 lakh shares by 10:47 IST on BSE, a 5.45 times surge over two-week average daily volume of 51732 shares. The stock increased 1.56% to Rs.1,141.95. Volumes stood at 57919 shares in the last session.HCL Technologies Ltd recorded volume of 10.56 lakh shares by 10:47 IST on BSE, a 4.55 times surge over two-week average daily volume of 2.32 lakh shares. The stock lost 9.44% to Rs.1,305.40. Volumes stood at 1.15 lakh shares in the last session.
1 month agoCapital Market - Live
Corporate
Corporate
Dr. Lal PathLabs schedules board meetingDr. Lal PathLabs will hold a meeting of the Board of Directors of the Company on 30 April 2026.Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Corporate
Board of Dr. Lal PathLabs recommends Third Interim dividendDr. Lal PathLabs announced that the Board of Directors of the Company at its meeting held on 30 January 2026, inter alia, have recommended the Third Interim dividend of Rs 3.5 per equity Share (i.e. 35%) , subject to the approval of the shareholders.Powered by Capital Market - Live
4 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 13.02%, vs industry avg of 13.41%
Over the last 5 years, market share decreased from 3.32% to 3.1%
Over the last 5 years, net income has grown at a yearly rate of 16.61%, vs industry avg of 42.52%